PolyPid Announces Private Placement for $16 Million in Gross Proceeds
PETACH TIKVA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq:PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has entered into a securities purchase agreement for a private placement financing (the “PIPE”) for $16.2 million in gross proceeds priced at the 5-day volume weighted average price as of January 2, 2024 of $4.81 per share. The PIPE syndicate is comprised of new and existing investors, including participation from new U.S. life sciences-focused investors, DAFNA Capital Management and Rosalind Advisors.
Related news for (PYPD)
- PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
- BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript
- 24/7 Market News Snapshot 09 June, 2025 – PolyPid Ltd. Ordinary Shares (NASDAQ:PYPD)
- PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints
- Breaking News: MoBot’s Latest Update as of 06/09/25 07:00 AM